Market closedNon-fractional
Black Diamond Therapeutics/BDTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Black Diamond Therapeutics
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Ticker
BDTX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
54
BDTX Metrics
BasicAdvanced
$350M
Market cap
-
P/E ratio
-$1.67
EPS
2.51
Beta
-
Dividend rate
Price and volume
Market cap
$350M
Beta
2.51
Financial strength
Current ratio
7.049
Quick ratio
6.835
Long term debt to equity
20.479
Total debt to equity
23.532
Management effectiveness
Return on assets (TTM)
-38.27%
Return on equity (TTM)
-78.81%
Valuation
Price to book
3.15
Price to tangible book (TTM)
3.15
Price to free cash flow (TTM)
-4.383
Growth
Earnings per share change (TTM)
-29.81%
3-year earnings per share growth (CAGR)
-11.11%
What the Analysts think about BDTX
Analyst Ratings
Majority rating from 6 analysts.
BDTX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$18M
-6.19%
Profit margin
0.00%
NaN%
BDTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.52
-$0.45
-$0.34
-$0.35
-
Expected
-$0.54
-$0.49
-$0.47
-$0.44
-$0.39
Surprise
-2.95%
-7.50%
-27.04%
-19.54%
-
BDTX News
AllArticlesVideos
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewsWire·2 months ago
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
GlobeNewsWire·2 months ago
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Black Diamond Therapeutics stock?
Black Diamond Therapeutics (BDTX) has a market cap of $350M as of July 27, 2024.
What is the P/E ratio for Black Diamond Therapeutics stock?
The price to earnings (P/E) ratio for Black Diamond Therapeutics (BDTX) stock is 0 as of July 27, 2024.
Does Black Diamond Therapeutics stock pay dividends?
No, Black Diamond Therapeutics (BDTX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Black Diamond Therapeutics dividend payment date?
Black Diamond Therapeutics (BDTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Black Diamond Therapeutics?
Black Diamond Therapeutics (BDTX) has a beta rating of 2.51. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Black Diamond Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.